Surging demand for effective weight-loss drugs in America is having a big impact on Denmark’s economy in the form of lower interest rates and a strengthening currency.

Denmark-based Novo Nordisk manufactures Wegovy and Ozempic, a GLP-1 drug that helps patients lower their blood sugar levels and lose upwards of 25 pounds.

The drugs, which were first to market in the US for the treatment of obesity, have sent Novo Nordisk’s market valuation soaring to the second most valuable company in Europe after luxury goods maker LVMH.

Novo Nordisk has seen its market value soar 38% year to date to $413 billion, which is more than Denmark’s estimated 2022 GDP of about $406 billion.